Trial Profile
Phase I Trial With Docetaxel, Oxaliplatin and S1 as First-line Treatment for Patients With Non-resectable Adenocarcinoma of the Oesophagus or Gastric
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 23 Jan 2016 Status changed from recruiting to completed, according to results presented at the 2016 Gastrointestinal Cancers Symposium.
- 01 Sep 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 31 Aug 2013 New trial record